कोशिश गोल्ड - मुक्त

CPHI & PMEC India poised to reshape pharma landscape

Chronicle Pharmabiz

|

November 27, 2025

EVOLVING from its traditional role as the world's supplier of affordable generics to a research-driven, technology-integrated global healthcare powerhouse, Indian pharmaceutical industry is undergoing a profound transformation.

- Our Bureau, Mumbai

CPHI & PMEC India poised to reshape pharma landscape

Indian pharmaceutical companies are increasingly investing in innovation, biosimilars, complex generics, and cutting-edge research. The integration of artificial intelligence, data analytics, and genomics is opening new frontiers in drug discovery, personalized medicine, and precision healthcare. These advancements are positioning India as a leader not just in manufacturing but also in the development of next-generation therapies and solutions.

At the same time the active pharmaceutical ingredients (API) industry in India also stands at the threshold of a transformation with backward integration and reduced import dependence, growth in high-value, niche APIs, improved regulatory compliance and quality focus, sustainability & Green API manufacturing, digital & virtual API supply chain models.

Impacted by global supply chain dynamics, shifting regulatory landscapes, and the desire for self-reliance, the API industry in the country is at a watershed moment.

Traditionally reliant on imports, especially from China, India has made significant strides in boosting its domestic API manufacturing capabilities.

India's unparalleled manufacturing scale, cost efficiency, and deep reservoir of scientific talent provide it with a competitive edge. The country's skilled workforce is driving innovation and ensuring the highest standards of quality and compliance. This blend of scale and expertise enables India to meet both domestic healthcare needs and the growing demands of international markets.

Continued government support through schemes like the PLI, coupled with a focus on sustainability and green chemistry, is fostering an environment conducive to long-term growth. The sector's commitment to environmental responsibility and sustainable manufacturing practices is enhancing its global reputation and appeal.

Chronicle Pharmabiz से और कहानियाँ

Chronicle Pharmabiz

US FDA fortifies alliance with Telangana DCA

A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

India exploring possibilities to expand WHO standards for Indian medicines

INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

Eli Lilly gets US FDA approval for Jaypirca

Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.

time to read

1 mins

December 11, 2025

Chronicle Pharmabiz

Haryana DCA focuses on quality overhaul

THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

DoC seeks inputs on trade issues faced with Japan

THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

AIOCD asks traders to strictly comply with ban on 35 FDCs

THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).

time to read

3 mins

December 11, 2025

Chronicle Pharmabiz

US FDA approves Bristol Myers Squibb's Breyanzi

Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

CN Water presents AQU@Sense MB

CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

Pharma logistics sees policy push as key catalyst for growth

INDIAN pharma's logistics sector is getting major boost from emerging policy support.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline

INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.

time to read

2 mins

December 11, 2025

Listen

Translate

Share

-
+

Change font size